Microbio Group, one of the largest biotech groups in Taiwan, is dedicated to research and development in innovative new drugs for oncology, immunology and unmet medical needs. The business scope covered by the companies and subsidiaries is dynamic, including health care, venture capital and organic retail channel. With a total investment of more than USD$750 million in the pipeline, Microbio focuses on developing first-in-class or best-in-class new drugs in botanical extracts, NCE, antibody, glycan molecule, aptamers and cell therapy. At Microbio, we have established platforms for post-biotics in-house fermentation, anti-body and aptamer development technology, equipping the Group with the capability in research and development to compete with international leading pharmaceutical companies. To learn more about Microbio group, please visit www.microbiogp.com.